Welcome to our dedicated page for Aurora Cannabis Common Shares news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis Common Shares stock.
Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a prominent Canadian company headquartered in Edmonton, Alberta, dedicated to the cultivation, production, and sale of high-quality cannabis for both medical and recreational use. The company's state-of-the-art facilities in Alberta embody advanced cultivation techniques that ensure the highest standards of quality, reliability, and safety in their products. Aurora's comprehensive portfolio includes renowned brands like Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, catering to a wide range of consumer preferences.
Aurora's operations extend beyond Canada, with significant international presence through medical cannabis exporting agreements. A notable subsidiary, Australis Capital Inc., plays a crucial role in participating in the U.S. cannabis market. The company's commitment to quality is further highlighted by its EU-GMP and TGA-GMP certified production facilities, ensuring compliance with rigorous international standards.
In recent developments, Aurora has launched three new cannabis-infused beverages targeted initially at veteran patients. These products, featuring innovative SōRSE® emulsion technology, offer an alternative form of cannabis consumption without the strong cannabis aroma or taste. Available in flavors like Neon Rush, Strawberry Pineapple Tropical Fizz, and Pineapple Coconut Fizz, these beverages are designed to enhance patient wellbeing with a refreshing and potent experience.
Financially, Aurora has achieved significant milestones, including the repayment of nearly $465 million in convertible debt and forecasting positive free cash flow for calendar 2024. The company has also strengthened its global footprint by acquiring MedReleaf Australia's majority equity, further solidifying its position in the Australian market. Aurora’s commitment to financial discipline and strategic expansions underscores its potential for sustainable growth.
Aurora's dedication to innovation and patient care is exemplified through its continuous development of new products and partnerships. Their recent launches include resin cartridges and pastilles in Australia, expanding their product range and enhancing patient access to premium medical cannabis. Additionally, the company's strategic moves in Europe, particularly in Germany, position it as a leader in the evolving cannabis landscape.
With a robust pipeline of products and strategic market expansions, Aurora Cannabis Inc. continues to pave the way for significant advancements in the global cannabis industry, committed to improving lives through high-quality, innovative cannabis products.
Aurora Cannabis (NASDAQ: ACB) has launched IndiMed, its first German-cultivated medical cannabis brand, manufactured at their EU-GMP facility in Leuna, Germany. This development follows Germany's recent cannabis decriminalization and positions Aurora as one of only three licensed cultivators in the country.
The initial product release is Island Sweet Skunk, a dried flower sativa variant containing 20% THC and <1% CBD, scheduled for availability on January 27. The product is cultivated under GACP and EU-GMP guidelines, featuring hand-harvested flowers that undergo controlled drying and laboratory testing for purity and potency.
As the world's largest medical cannabis company in legal markets, Aurora's expansion in Germany demonstrates its commitment to serving the country's growing patient base with locally produced, high-quality medical cannabis products.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming third quarter 2025 financial results conference call. The event is scheduled for Wednesday, February 5, 2025, at 8:00 a.m. Eastern Time (6:00 a.m. Mountain Time). The company will release its financial results before markets open on the same day.
The conference call will be hosted by Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, and will include a question and answer session. Investors can access the webcast through the company's investor relations website.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB) has launched an internship program at its EU-GMP facility in Leuna, Germany, partnering with Erfurt University of Applied Sciences. The six-month program targets students from the Horticultural Crop Production course, offering hands-on experience in medical cannabis cultivation.
The program will cover all aspects of medical cannabis production, including cloning, care, harvesting, packaging, and cleaning, along with participation in research and development projects. The Leuna facility is among the few sites in Germany authorized to grow medical cannabis, featuring state-of-the-art indoor cultivation methods and sustainable practices.
According to Michael Simon, President of Aurora Europe (Interim), this initiative aims to provide students with unparalleled industry insights while collaborating with leading experts in the global medical cannabis sector.
Aurora Cannabis Inc. (NASDAQ: ACB) has announced a distribution partnership between MedReleaf Australia and The Entourage Effect to expand access to premium medical cannabis products in Australia. The Entourage Effect will serve as a wholesaler for MedReleaf Australia's portfolio, including CraftPlant, Aurora, and IndiMed brands.
The partnership aims to strengthen Aurora's distribution network in Australia through MedReleaf Australia, its wholly-owned subsidiary that meets TGA-GMP standards. This collaboration represents Aurora's commitment to expanding its presence in the growing Australian medical cannabis market while ensuring broader access to their medical cannabis portfolio.
Aurora Cannabis (NASDAQ: ACB) has announced new medical cannabis product developments from its research facility, Aurora Coast. The company introduced several innovations including: Aurora CBD Varius (1g, 510 Cartridge), MedReleaf Esprit De Corps (5g and 15g) with 20-29% THC, MedReleaf Sedamen (1g, 510 Cartridge), MedReleaf Noculus (5g and 15g) with 25-31% THC, and WMMC Seasonal Stash - Frosted Alpine (10g) with 24-30% THC. These products are available through AuroraMedical.com, demonstrating Aurora's commitment to providing patients with premium cannabis products.
Aurora Cannabis (NASDAQ: ACB) announces expansion of its recreational product portfolio with new offerings across Greybeard, San Rafael '71, and Tasty's brands. The new lineup includes Greybeard's Banana Gas Pure Live Resin Vape, Country Lemon Terp Slush, and Critical Diesel Pre-Rolls; San Rafael '71's 20 Pack Pre-Rolls; and Tasty's Diamond Infused Pre-Rolls in Mango, Honeydew, and Melon varieties, plus a Grape 510 Vape. These products focus on delivering premium, science-driven offerings with emphasis on flavor and intensity for Canadian cannabis consumers.
Aurora Cannabis reported strong fiscal Q2 2025 results with record adjusted EBITDA of $10.1 million, up 210% year-over-year. Total net revenue reached $81.1 million, a 29% increase driven by 41% growth in global medical cannabis and 21% growth in plant propagation. International revenue grew 93% to $35 million, exceeding Canadian Medical revenue for the first time. The company maintains a strong balance sheet with $152 million in cash and a debt-free cannabis business. Medical cannabis contributed 76% of consolidated net revenue with a 68% adjusted gross margin. The company reaffirms its target of positive free cash flow by December 31, 2024.
Aurora Cannabis (NASDAQ: ACB) (TSX: ACB), a leading global medical cannabis company, has announced its upcoming second quarter 2025 earnings conference call scheduled for Wednesday, November 6, 2024, at 8:00 a.m. Eastern Time. The financial results will be released before market opening on the same day. Chairman and CEO Miguel Martin and CFO Simona King will host the conference call and Q&A session.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), in partnership with MedReleaf Australia, has launched an enhanced range of premium medical cannabis oils in Australia. The new products include various cannabinoid ratios to meet diverse patient needs, such as Aurora THC 25 (Sativa and Indica), Aurora 12.5:12.5, Aurora 50:50, and Aurora 10:100 oils, all in 30mL bottles.
These oils are developed and manufactured at Aurora's Canadian TGA and EU GMP certified facility, offering healthcare providers and patients a broader selection of treatment options. The expanded product portfolio demonstrates Aurora's commitment to advancing patient care through high-quality, science-driven cannabis solutions.
Key features of the new cannabis oil products include comprehensive cannabinoid profiles, high standards of quality and safety, and a broad selection for customized patient care. Healthcare professionals can contact MedReleaf Australia's clinical support team for additional information.
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has announced a research collaboration with the University of British Columbia (UBC), funded by Genome British Columbia. The project, titled 'Genomics-enabled Aroma Breeding in Cannabis,' aims to validate genetic and chemical markers for fruity aroma in cannabis, a key consumer preference trait.
Led by Dr. Jose Celedon from Aurora and Professor Joerg Bohlmann from UBC, this research aligns with Aurora's breeding goals and will enhance its breeding program's accuracy and efficiency. The project will utilize Aurora's advanced cannabis genetic library and recent patents on fruity aroma markers. Aurora will contribute through sensory analysis and bioinformatic analyses, while UBC will focus on sequencing transcriptomes, analyzing volatile chemistry, and characterizing genes responsible for fruity aromas.
This collaboration demonstrates Aurora's commitment to innovation and scientific advancement in the cannabis sector, potentially impacting future product development and consumer satisfaction.
FAQ
What is the current stock price of Aurora Cannabis Common Shares (ACB)?
What is the market cap of Aurora Cannabis Common Shares (ACB)?
What is Aurora Cannabis Inc. primarily known for?
Where is Aurora Cannabis Inc. headquartered?
What are some of the brands under Aurora Cannabis?
What recent products has Aurora Cannabis launched?
What is Aurora's financial outlook for 2024?
What significant acquisitions has Aurora made recently?
What certifications do Aurora's production facilities hold?
How does Aurora contribute to the U.S. cannabis market?
What international operations does Aurora have?
How does Aurora ensure the quality of its products?
